secwatch.observer — SEC 8-K summary
======================================

Issuer:     LABCORP HOLDINGS INC. (LH)
CIK:        0000920148
Form:       8-K
Filed at:   2026-08-14T12:55:14+00:00
Accession:  0000920148-26-000182
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Labcorp EVP Bailey resigns; Caveney to lead Biopharma Lab Services
------------------------------------------------------------------

- Megan D. Bailey resigns as EVP & President, Central Laboratories and International, effective Sept 4, 2026.
- Brian J. Caveney, M.D. becomes EVP & President, Biopharma Laboratory Services and Chief Medical & Scientific Officer on Sept 1, 2026.
- Caveney will oversee Early Development Research Laboratories and Central Laboratories businesses.
- Caveney previously led Early Development Research Laboratories and served as Chief Medical and Scientific Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/920148/000092014826000182/0000920148-26-000182-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/920148/000092014826000182/lh-20260811.htm
  HTML page:      https://secwatch.observer/filing/0000920148-26-000182

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer